Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06190951
Title A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Regeneron Pharmaceuticals
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
USC Norris Comprehensive Cancer Center RECRUITING Los Angeles California 90033 United States Details
UCSF RECRUITING San Francisco California 94143 United States Details
St John's Cancer Institute RECRUITING Santa Monica California 90404 United States Details
Hartford Hospital RECRUITING Hartford Connecticut 06102 United States Details
University of Massachusetts Chan Medical School RECRUITING Worcester Massachusetts 01655 United States Details
Rutgers Cancer Institute of New Jersey RECRUITING New Brunswick New Jersey 08901 United States Details
Seidman Cancer Center RECRUITING Cleveland Ohio 44106 United States Details
Cleveland Clinic Foundation RECRUITING Cleveland Ohio 44195 United States Details
University of Tennessee Medical Center RECRUITING Knoxville Tennessee 37920 United States Details
University of Virginia RECRUITING Charlottesville Virginia 22908 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field